Every 424B that Envoy Medical (COCH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical is registering up to 150,803,850 shares of Class A common stock underlying pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 shares of common stock and 27,053,850 pre-funded warrants sold in a best-efforts public offering at $0.40 per share and accompanying warrants. The deal implies a maximum gross raise of about $30.0 million and estimated net proceeds of roughly $27.8 million before any warrant exercises. There is no minimum offering amount, and H.C. Wainwright is acting as exclusive placement agent.
Common stock outstanding would rise from 28,934,960 to 103,934,960 shares if all pre-funded warrants are exercised and none of the new common or placement agent warrants are exercised. Company insiders are committing about $8.4 million of the raise. Envoy remains a loss-making, emerging growth medical device company, advancing its fully implanted Acclaim cochlear implant through a pivotal trial while facing Nasdaq listing compliance pressures and substantial ongoing capital needs.
Envoy Medical, Inc. is registering up to 150,803,850 shares of Class A common stock issuable from pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 new shares in a primary offering of stock and warrants at $0.40 per share and accompanying warrants.
The company expects gross proceeds of about $30.0 million and estimated net proceeds of roughly $27.8 million, with no minimum offering requirement in this reasonable best-efforts deal led by H.C. Wainwright. Company insiders plan to buy about 21.0 million shares plus warrants for approximately $8.4 million. Shares outstanding are expected to rise from 28,934,960 to 103,934,960, assuming all pre-funded warrants are exercised and no additional warrants are exercised.
Envoy is a hearing-health company developing the fully implanted Acclaim cochlear implant, now in the final stage of a pivotal U.S. trial, and has never been profitable. It reported net losses of $17.2 million for the nine months ended September 30, 2025 and carries a going-concern warning. The company also faces Nasdaq compliance pressures related to market value and minimum bid price listing standards.
Envoy Medical, Inc. (COCH) is offering securities in a prospectus supplement that discloses a public offering price of $0.1131 per unit, placement agent fees of $340,001, and proceeds to the company before expenses of $3,660,007. The document lists intended uses of proceeds including continued R&D and clinical trials for the Acclaim CI product candidate, seeking regulatory approvals outside the United States, building sales and distribution infrastructure, reliance on third-party suppliers, IP protection, hiring personnel, and general public-company infrastructure.
The filing enumerates material risk factors affecting investors: company financial performance; market-price volatility of Class A common stock; regulatory, clinical and design-change risks for medical devices; reimbursement and competitive risks; supplier or production disruptions; capital-raising needs; interest rate, tariff and tax changes; legal and regulatory proceedings; potential loss of intellectual property; and catastrophic events such as war or terrorism. The supplement also details outstanding and potential dilutive instruments including multiple classes of warrants, options, Series A preferred conversion, and other securities.
Envoy Medical, Inc. files a prospectus supplement describing a securities offering and related risk factors. The company lists numerous operational and industry risks including regulatory uncertainty for medical devices, potential product design changes, supplier and manufacturing disruptions, reimbursement policy shifts, competition and alternative therapies, capital needs and financing availability, intellectual property risks, legal and regulatory proceedings, and catastrophic events. The prospectus also details planned uses of proceeds to advance Acclaim CI clinical development, pursue additional regulatory approvals, build commercial infrastructure, rely on third-party suppliers, expand intellectual property, and hire personnel. The filing discloses potential dilution from various warrants, options and convertible preferred shares (examples: 14,166,666 Public Warrant shares; 3,104,511 Meteora Warrant shares; 3,588,406 shares on conversion of Series A Preferred; and equity incentive plan options). It incorporates multiple prior reports by reference.
The company has filed a prospectus supplement to suspend its at-the-market stock offering program. Under the existing At The Market Offering Agreement with Roth Capital Partners, it had previously sold 174,012 shares of Class A Common Stock for aggregate gross proceeds of $266,060.
The supplement suspends the ATM program and the continuous offering under the related prospectuses effective on September 22, 2025, and no further sales can occur unless a new prospectus supplement is filed, although the ATM Agreement itself remains in force. The Class A Common Stock trades on the Nasdaq Capital Market under the symbol COCH, with a last reported sale price of $1.31 per share on September 19, 2025. The filing also notes that sales under Form S-3 are limited by the one-third public float cap when non-affiliate equity market value is under $75,000,000.